Ablynx - BioCapital Company of the Year 2018
Ablynx NV CEO Edwin Moses sounds the gong, celebrating the company’s recent ‘BioCapital Company of the Year’ award. This award is presented yearly by Life Sciences Partners (LSP) during the BioCapital Europe Conference in Amsterdam.
LSP was proud to offer Ablynx the “BioCapital Company of the Year” award on February 6th 2018. LSP has been hosting The BioCapital Europe conference in Amsterdam for the past 16 years. The event brings together some of the most innovative healthcare companies across Europe. The “Company of the Year” is selected by approximately 250 delegates on the day of the conference. Ablynx was the clear winner at this year’s event, thanks to its outstanding performance.
Moses embraced the award in recognition of the exceptional progress the company has made since its IPO on Euronext Brussels (ticker symbol: ABLX) in 2007. The company has a unique Nanobody drug discovery and development platform which it uses to develop new medicines in various therapeutic areas. In October 2017, the company presented positive Phase III data validating the potential of its lead compound caplacizumab to become a key component of the new standard-of-care for acquired thrombotic thrombocytopenic purpura (aTTP), a life-threatening blood clotting disorder, with potential approval and first launch anticipated in 2018.
For more information: www.ablynx.com